Satellos Bioscience Inc.

Satellos Bioscience Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026. Additionally, the FSHD Canada Foundation has agreed to provide up to US$5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD. This funding will support a Phase 2 study evaluating forazapadin at two dose levels.

Satellos Bioscience reported a net loss of $11.7 million for Q2 2026, increasing from $5.6 million in Q2 2025, with R&D expenses significantly rising to $9.6 million. The company announced that its drug candidate, SAT-3247, received FDA Fast Track Designation for Duchenne muscular dystrophy (DMD). Interim data from the TRAILHEAD Phase 2 adult DMD study showed signs of muscle regeneration and improved quality of life, with data from the BASECAMP pediatric study expected in Q4 2026. Satellos maintains a strong financial position with $61.8 million in cash and investments, providing runway through 2027.

Satellos Bioscience received FDA Fast Track Designation for SAT-3247 for Duchenne muscular dystrophy (DMD). The company reported positive six-month follow-up data from its TRAILHEAD Phase 2 adult DMD study, showing reduced muscle fat, increased total effort, and improved quality of life, consistent with muscle regeneration. Enrollment is advancing in the BASECAMP Phase 2 pediatric study, with data expected in Q4 2026. Satellos also reported a strong cash position of $61.8 million, providing a runway through 2027, despite increased R&D and G&A expenses leading to a net loss of $11.7 million for Q2 2026.

Satellos Bioscience Inc. has filed an amended and restated short form base shelf prospectus, allowing the company to offer up to US$300,000,000 in various securities over a 25-month period. The securities that may be offered include Common Shares, Preferred Shares, Warrants, Units, Subscription Receipts, and Debt Securities. This filing updates a previous prospectus from October 29, 2025, providing flexibility for future capital raising.

Satellos Bioscience announced positive six-month interim data from its TRAILHEAD study for SAT-3247 in adults with Duchenne muscular dystrophy (DMD). The investigational drug showed reduced muscle fat fraction, increased total effort, stable strength, and lower creatine kinase (CK) levels. The safety profile remained favorable and consistent with previous reports, with all four participants showing improvements in key metrics despite the advanced stage of their disease. The company plans to complete enrollment in the BASECAMP study and initiate US clinical trial sites for TRAILHEAD in Q3.

Satellos Bioscience Inc. announced positive six-month interim data from its TRAILHEAD study for investigational drug SAT-3247 in adults with Duchenne muscular dystrophy. The results showed reduced muscle fat fraction, increased total upper limb effort, stable strength, and lower muscle damage biomarkers. The drug maintained a favorable safety profile, and the company plans to complete enrollment in its BASECAMP study and initiate US clinical trial sites for TRAILHEAD in the third quarter.

Satellos Bioscience announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAT-3247 for the treatment of Duchenne Muscular Dystrophy (DMD). This designation, along with prior Orphan Drug and Rare Pediatric Disease designations, aims to expedite the development and review of the drug. The company is currently advancing SAT-3247 through its Phase 2 BASECAMP and TRAILHEAD studies, with additional data anticipated in the second half of 2026.

Satellos Bioscience Inc. announced it will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases (ICNMD) in Florence, Italy, from July 7–11, 2026. The presentations will include a poster detailing six-month follow-up data from participants who completed the Phase 1b SAT-3247-CL-101 trial and enrolled in the ongoing Phase 2 TRAILHEAD (LT-001) trial. Wildon Farwell, MD, MPH, Satellos' Chief Medical Officer, will present both the poster and a Showcase Theatre presentation on advancing muscle repair with SAT-3247, an investigational oral small molecule for degenerative muscle diseases like Duchenne muscular dystrophy.

Satellos Bioscience Inc. announced it will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases (ICNMD) in Florence, Italy, from July 7-11, 2026. The presentations will include a poster highlighting six-month follow-up data from participants who completed the Phase 1b SAT-3247-CL-101 trial and enrolled in the ongoing Phase 2 TRAILHEAD study. Additionally, the company's Chief Medical Officer will deliver a Showcase Theatre presentation on advancing muscle repair with SAT-3247, an investigational oral drug for Duchenne muscular dystrophy and other degenerative muscle diseases.

Satellos Bioscience Inc. held its annual meeting of shareholders virtually on June 17, 2026. Shareholders elected all nine director nominees to hold office until the next annual meeting. Additionally, PricewaterhouseCoopers LLP was appointed as the company's auditor, with directors authorized to fix its remuneration. Approximately 55.33% of the company's issued and outstanding shares were represented at the meeting.